Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Stems Q2 Losses While Hunting for Products and Partners

NEW YORK (GenomeWeb News) — Compugen yesterday reported it earned no revenues for the second quarter of 2007, while R&D spending was down 15 percent and net loss was cut 11 percent.
The company reported $5,000 in revenue for the second quarter of 2006.           .
Compugen said R&D spending in the quarter dipped to $2.3 million from $2.7 million year over year.
Net loss was lowered slightly to $3.2 million from $3.6 million over the same quarter last year.
As of June 30, Compugen had $18.8 million in cash, cash equivalents, deposits, and marketable securities.
Compugen CEO Alex Kotzer said the company saw “significant progress” in “product candidate development, negotiations for new licensing agreements, new engine creation and discovery validation.”
Kotzer said Compugen is focused on developing a “discovery engine” targeted at identifying existing drug molecules that have “important, but currently unknown, therapeutic indications.”

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.